Vanessa Lucey, PhD, MBA, is a Director, WW Oncology Commercial, Early Assets at Bristol Myers Squibb (BMS). Prior to BMS, Dr Lucey was the director of Clinical Accelerator and the CRI Venture Fund at the Cancer Research Institute, where she managed the program’s scientific and investment strategy for $100M evergreen venture fund.

Prior to joining CRI, Dr Lucey performed research for 12 years as a scientist in immunology. She received her BS in Biology from Fordham University and prior to graduate school, Dr Lucey worked as a research technician studying the co-stimulatory molecule ICOS in Graft-versus-Host-Disease and Graft-versus- Leukemia. She received her PhD from Albert Einstein College of Medicine studying T cell activation. She completed a postdoctoral fellowship at NYU School of Medicine, studying the role of a common gene variant and its effects on Graft-Versus-Host- Disease. Dr Lucey received her MBA in Management/Finance from Mercy College School of Business. She has published 28 peer-reviewed papers in top tier journals.

Maria Jure-Kunkel, DVM, PhD, is currently Vice-President of Translational Medicine at Genmab, where she leads translational strategies for programs in solid tumors and hem-oncology. Prior to Genmab, she led Translational Medicine and Discovery/Translational Research teams at MedImmune/AstraZeneca and at Bristol-Myers Squibb. In her 20+ years of pharmaceutical experience, Dr Jure-Kunkel has been the recipient of several patents in the field of Immuno-Oncology for agents based on diverse targeting modalities (monoclonal and bispecific antibodies, small molecules), CD3-bispecific antibodies in hem-oncology, had the privilege to lead and contribute to the development and registration of several IO agents, and generated biomarker strategies leading to the development of companion diagnostics.

Dr Jure-Kunkel received her DVM from the University of Uruguay, School of Veterinary Medicine, a PhD in Immunopathology from Cornell University, and post-doctoral training from Rockefeller University.

Hongtao Lu, PhD is Co-Founder and Chief Scientific Officer (CSO) of Elpiscience. Trained as an immunologist, Hongtao is a 20-year industry veteran, with R&D experience developing both small molecule and biologic-based therapies across several therapeutic areas, including autoimmune diseases, oncology, and neuroscience. Before co-founding Elpiscience, Hongtao co-founded Zai Lab, a NASDAQ-listed company, as its Vice President and helped to build a robust pipeline focusing on oncology and autoimmune diseases. Prior to Zai Lab, he was with GlaxoSmithKline (GSK) as the founding head and senior director of Neuroimmunology Discovery Performance Unit (NI-DPU), where he led a team of 70 biologists and chemists focusing on drug discovery in multiple sclerosis and other neurodegenerative diseases including Parkinson's disease. While at GSK, he also successfully built this R&D team and the pipeline in only 5 years, producin three clinical-stage assets and four pre-clinical programs. Dr Lu spent his early career with Berlex Biosciences and Bayer Schering Pharma, where he conducted target identification and validation in autoimmune inflammatory diseases and oncology. Dr Lu holds a PhD in Regulatory Biology and conducted his graduate research at the Cleveland Clinic Foundation, focusing on MHC class II gene regulation. After receiving his doctorate, Dr Lu completed his post-doctoral fellowship at Yale University School of Medicine under the guidance of Dr. Richard Flavell, where he worked on T cell differentiation and signal transduction pathway.

Jacqueline Karmel is currently the Director of the Scientific Collaborations network imCORE (immunotherapy Centers of Research Excellence). imCORE is one of the largest industry and academia oncology partnerships with a global network of 25 of the leading scientific and clinical research centres for cancer immunotherapy.

Prior to this role Ms Karmel spent the previous 8 years working both as an employee and consultant for Genentech as the oncology lead for the global operational strategy for Genentech Research and Early Development (gRED). She was responsible for identifying and enabling the optimal clinical development opportunities outside of the US for both small molecules and biologics, including atezolizumab. During this time Roche acquired Genentech, at which point Ms Karmel lead the way for gRED to navigate and utilize the global wealth of country level knowledge and expertise within the multiple country affiliate offices of Roche to further assist in the operationalization of the Genentech early oncology portfolio.

Ms Karmel has over 30 years’ experience in the Biotechnology and Pharmaceutical Industry, 20 years being focused on oncology and haematology. She was the European Headquarters site co-Head for Millennium Pharmaceuticals Ltd, and Director of Clinical Operations where she worked on the successful clinical development of bortezomib for hematological malignancies as well as investigating proteasome inhibition in multiple solid tumours. She was integral to the licensing of bortezomib, which led to partnering with Johnson and Johnson where she was part of the Joint Clinical Steering Committee.

Jay Fine is President, Research & Development at EvolveImmune Therapeutics, a development-stage company located in the New Haven, CT area. EvolveImmune is pioneering a new category of precision-engineered immuno-oncology therapeutics, which leverage integrated CD2 costimulation to overcome cancer cell resistance to current anti-tumor therapies. Its lead asset, EVOLVE104 will initiate first-in-human clinical trials in 2025. Previously, Jay was a Senior Vice President, Global Therapeutic Area Head and Research Site Head at Boehringer Ingelheim. Jay’s teams played seminal roles in the discovery and development of Skyrizi™ and Spevigo™, and delivered over 30 molecules into clinical development. Jay has held leadership positions at Roche and Schering-Plough, and at the National Cancer Institute. He received his B.S. degree from Cornell University and his Ph.D. degree from the University of Rochester Medical School. He is the author of over 75 scientific publications and patents and has received numerous honors and awards throughout his career.

Caleb Lareau, PhD, is an Assistant Member in the Computational and Systems Biology Program at Sloan Kettering Institute. He joined MSK from Stanford University where he was a Stanford Science Fellow and Parker Scholar at the Parker Institute for Cancer Immunotherapy. Originally from Oklahoma, Dr Lareau completed his undergraduate studies at the University of Tulsa before attending Harvard University for his graduate degrees.

Jamie Goldfarb was diagnosed with Stage IV melanoma in January 2011, when her son was just 11 weeks old. Upon diagnosis, her oncologist told her that he would do everything in his power to buy her 6 more months. Ms Goldfarb joined a clinical trial at the National Cancer Institute (NCI) and is now completely disease-free. Having worked in patient recruitment for 8 years and having her own life saved by a clinical trial, Ms Goldfarb's personal mission is to spread information about the importance of medical research as far and wide as possible. To this end, she is involved with the Melanoma Research Alliance, the Melanoma Research Foundation, the Melanoma International Foundation, CISCRP, the Alliance for Regenerative Medicine, the Association of Clinical Research Professionals, and Imerman Angels. She also serves as a research advocate for NCI, and works one-on-one with people with cancer to help them navigate their treatment options, including clinical trials.

Ylenia Paleari, PhD, is a rare disease expert with almost a decade of experience in the industry. She has worked at Chiesi Farmaceutici SpA for five years, leading the Global Rare Diseases R&D Patient Engagement team. Her team is responsible for incorporating the patient perspective into every aspect of the drug development process. With her deep knowledge of the rare disease space and experience in academia and industry, Dr Paleari is committed to translating basic scientific research into effective therapeutic interventions. She has held various positions in academia and industry and moved from pre-clinical to clinical research. In addition to her work at Chiesi, Dr Paleari serves as a local patient association board member dedicated to raising awareness about rare cancers. Dr Paleari is passionate about making a positive impact in patients' lives, and her work reflects that dedication.

Accomplished professional with over 20 years of experience in clinical research in various roles (Clinical Operations, GCP Compliance, Transparency and Disclosure and Digital Innovation). Ms Minetti is currently working at Chiesi Farmaceutici in the R&D Global Clinical Development department, where she most recently started in her new position as Patient Research Partner, responsible for building and integrating a more patient-informed approach in clinical development

Mythili Koneru, MD, is Chief Medical Officer of Legend Biotech, charged with overseeing all clinical development and medical affairs activities.

Michael E. Meyers, is Vice Chairman, Head of M&A and Strategic Advisory Services at H.C. Wainwright & Co. Mr. Meyers has ~30 years of public health, investment banking, venture capital, asset management and operating experience in healthcare, with an emphasis on the life sciences and health care delivery. Over the course of his career, Mr. Meyers has advised on ~ $150 billion of strategic and financial transactions, the latter spanning the capital structure, including royalty financings. Previously, Mr. Meyers was Head of Investment Banking with T.R. Winston & Company; CEO and CIO of Arcoda Capital Management; Managing Director, Partner and Member of the Board of Global Biomedical Partners AG, a life sciences venture capital firm; Director of healthcare investment banking with Merrill Lynch & Co.; Vice President of Health Care Investment Banking with Cowen & Company; and a research associate with Hambrecht & Quist. Mr. Meyers serves on the Board of Trustees of the Ronald Reagan UCLA Medical Center, and the University of Southern California’s Board of Councilors for the Stevens Center for Innovation and School of Dramatic Arts. Mr. Meyers holds an M.P.H. in Health Policy and Management from Columbia University, and an A.B. in Biology from Brandeis University.